Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma

Kristy A. Warner, Felipe Nör, Gerson A. Acasigua, Manoela D. Martins, Zhaocheng Zhang, Scott A. McLean, Matthew E. Spector, Douglas B. Chepeha, Joseph Helman, Michael J. Wick, Christopher A. Moskaluk, Rogerio M. Castilho, Alexander T. Pearson, Shaomeng Wang, Jacques E. Nör*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Purpose: There are no effective treatment options for patients with advanced adenoid cystic carcinoma (ACC). Here, we evaluated the effect of a new small molecule inhibitor of the MDM2-p53 interaction (MI-773) in preclinical models of ACC. Experimental Design: To evaluate the anti-tumor effect of MI-773, we administered it to mice harboring three different patientderived xenograft (PDX) models of ACC expressing functional p53. The effect of MI-773 on MDM2, p53, phospho-p53, and p21 was examined by Western blots in 5 low passage primary human ACC cell lines and in MI-773-treated PDX tumors. Results: Single-agent MI-773 caused tumor regression in the 3 PDX models of ACC studied here. For example, we observed a tumor growth inhibition index of 127% in UM-PDX-HACC-5 tumors that was associated with an increase in the fraction of apoptotic cells (P = 0.015). The number of p53-positive cells was increased in MI-773-treated PDX tumors (P < 0.001), with a correspondent shift in p53 localization from the nucleus to the cytoplasm. Western blots demonstrated that MI-773 potently induced expression of p53 and its downstream targets p21, MDM2, and induced phosphorylation of p53 (serine 392) in low passage primary human ACC cells. Notably, MI-773 induced a dose-dependent increase in the fraction of apoptotic ACC cells and in the fraction of cells in the G1 phase of cell cycle (P < 0.05). Conclusions: Collectively, these data demonstrate that therapeutic inhibition of the MDM2-p53 interaction with MI-773 activates downstream effectors of apoptosis and causes robust tumor regression in preclinical models of ACC.

Original languageEnglish
Pages (from-to)3550-3559
Number of pages10
JournalClinical Cancer Research
Issue number14
StatePublished - 15 Jul 2016
Externally publishedYes


Dive into the research topics of 'Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma'. Together they form a unique fingerprint.

Cite this